BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

605 related articles for article (PubMed ID: 20001559)

  • 1. Targeting cancer with phosphodiesterase inhibitors.
    Savai R; Pullamsetti SS; Banat GA; Weissmann N; Ghofrani HA; Grimminger F; Schermuly RT
    Expert Opin Investig Drugs; 2010 Jan; 19(1):117-31. PubMed ID: 20001559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease.
    Cheng J; Grande JP
    Exp Biol Med (Maywood); 2007 Jan; 232(1):38-51. PubMed ID: 17202584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents.
    Lugnier C
    Pharmacol Ther; 2006 Mar; 109(3):366-98. PubMed ID: 16102838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphodiesterase inhibitors in airways disease.
    Fan Chung K
    Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An update on cyclic nucleotide phosphodiesterase (PDE) inhibitors: phosphodiesterases and drug selectivity.
    Gupta R; Kumar G; Kumar RS
    Methods Find Exp Clin Pharmacol; 2005 Mar; 27(2):101-18. PubMed ID: 15834463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of phosphodiesterase isoforms 2, 5, and 9 in the regulation of NO-dependent and NO-independent cGMP production in the rat cervical spinal cord.
    de Vente J; Markerink-van Ittersum M; Vles JS
    J Chem Neuroanat; 2006 Jun; 31(4):275-303. PubMed ID: 16621445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclic nucleotide phosphodiesterases.
    Essayan DM
    J Allergy Clin Immunol; 2001 Nov; 108(5):671-80. PubMed ID: 11692087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS.
    Andersson KE; Uckert S; Stief C; Hedlund P
    Neurourol Urodyn; 2007 Oct; 26(6 Suppl):928-33. PubMed ID: 17806124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future.
    Uckert S; Hedlund P; Andersson KE; Truss MC; Jonas U; Stief CG
    Eur Urol; 2006 Dec; 50(6):1194-207; discussion 1207. PubMed ID: 16815627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors.
    Verghese MW; McConnell RT; Strickland AB; Gooding RC; Stimpson SA; Yarnall DP; Taylor JD; Furdon PJ
    J Pharmacol Exp Ther; 1995 Mar; 272(3):1313-20. PubMed ID: 7891349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of apoptosis by an inhibitor of cAMP-specific PDE in malignant murine carcinoma cells overexpressing PDE activity in comparison to their nonmalignant counterparts.
    Marko D; Romanakis K; Zankl H; Fürstenberger G; Steinbauer B; Eisenbrand G
    Cell Biochem Biophys; 1998; 28(2-3):75-101. PubMed ID: 9515161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potentiation of erectile response and cAMP accumulation by combination of prostaglandin E1 and rolipram, a selective inhibitor of the type 4 phosphodiesterase (PDE 4).
    Bivalacqua TJ; Champion HC; Rajasekaran M; Sikka SC; Kadowitz PJ; Doherty PC; Hellstrom WJ
    J Urol; 1999 Nov; 162(5):1848-55. PubMed ID: 10524946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification, characterization, and functional role of phosphodiesterase type IV in cerebral vessels: effects of selective phosphodiesterase inhibitors.
    Willette RN; Shiloh AO; Sauermelch CF; Sulpizio A; Michell MP; Cieslinski LB; Torphy TJ; Ohlstein EH
    J Cereb Blood Flow Metab; 1997 Feb; 17(2):210-9. PubMed ID: 9040501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of cyclic nucleotide phosphodiesterase isozymes in intact canine trachealis.
    Torphy TJ; Zhou HL; Burman M; Huang LB
    Mol Pharmacol; 1991 Mar; 39(3):376-84. PubMed ID: 1848659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential phosphodiesterase expression and cytosolic Ca2+ in human CNS tumour cells and in non-malignant and malignant cells of rat origin.
    Vatter S; Pahlke G; Deitmer JW; Eisenbrand G
    J Neurochem; 2005 Apr; 93(2):321-9. PubMed ID: 15816855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification, characterization and functional role of phosphodiesterase isozymes in human airway smooth muscle.
    Torphy TJ; Undem BJ; Cieslinski LB; Luttmann MA; Reeves ML; Hay DW
    J Pharmacol Exp Ther; 1993 Jun; 265(3):1213-23. PubMed ID: 8389856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of phosphodiesterase in regulation of calcium current in isolated cardiac myocytes.
    Simmons MA; Hartzell HC
    Mol Pharmacol; 1988 Jun; 33(6):664-71. PubMed ID: 2454387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphodiesterase II, the cGMP-activatable cyclic nucleotide phosphodiesterase, regulates cyclic AMP metabolism in PC12 cells.
    Whalin ME; Scammell JG; Strada SJ; Thompson WJ
    Mol Pharmacol; 1991 Jun; 39(6):711-7. PubMed ID: 1646946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oocyte maturation involves compartmentalization and opposing changes of cAMP levels in follicular somatic and germ cells: studies using selective phosphodiesterase inhibitors.
    Tsafriri A; Chun SY; Zhang R; Hsueh AJ; Conti M
    Dev Biol; 1996 Sep; 178(2):393-402. PubMed ID: 8812137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sulindac and its derivatives: a novel class of anticancer agents.
    Haanen C
    Curr Opin Investig Drugs; 2001 May; 2(5):677-83. PubMed ID: 11569947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.